journal article·2026-07

Regulating HIF-2α stabilization with an intelligent switchable nanoplatform for tumor immunity reprogramming and enhanced therapy

Zelun Li, Guanhua Qiu, Wenwen Guo, Yuanquan Zhao, Yangchun Du, Huimin Li, Fumao Yang, Guozhen Huang, Ruibiao Fu, Yan Zou, Tingting Tan, Jie Chen, Xiaofeng Dong

Biomaterials· Volume 330
Publisher page

Abstract

Chronic hypoxia is a critical barrier to the effective treatment of solid tumors, including hepatocellular carcinoma (HCC), as it not only restricts the oxygen supply required for sonodynamic therapy (SDT) but also upregulates hypoxia-inducible factor-2α (HIF-2α), thereby accelerating tumor progression, inducing abnormal angiogenesis, suppressing antitumor immune responses, and diminishing the efficacy of targeted therapies. Here, we developed an intelligent switchable organic-inorganic hybrid nanoplatform (VitK3/P-Ce6@H-MnO2) that integrates oxygen self-supply, reactive oxygen species (ROS) storm induction, and immune microenvironment reprogramming. The acidic tumor microenvironment serves as an "endogenous switch," triggering the decomposition of H-MnO2 to release oxygen and Vitamin K3, thereby alleviating chronic hypoxia, facilitating HIF-2α degradation, and providing oxygen support for Ce6-mediated SDT. Upon ultrasound exposure as an "exogenous switch," activated Ce6, together with Vitamin K3 and Mn2+, induces a robust ROS storm, resulting in mitochondrial dysfunction and immunogenic cell death (ICD), while effectively reprogramming the chronic hypoxia-HIF-2α-driven immunosuppressive tumor microenvironment. Furthermore, in vivo studies demonstrated that Lenvatinib therapy, when combined with the nanoplatform, further suppressed chronic hypoxia-HIF-2α-driven abnormal angiogenesis, enhanced CD8+ T-cell infiltration, and boosted antitumor immune responses, ultimately achieving a potent synergistic therapeutic effect and promoting the conversion of "cold tumors" into "hot tumors." This study provides strong experimental evidence that nanoplatform-mediated immune microenvironment reprogramming represents a precisely controllable and highly effective therapeutic strategy for solid tumors, with promising translational potential in hepatocellular carcinoma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy10.1038/s41571-023-00825-3 ↗
2. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment10.1016/S0140-6736(25)01042-6 ↗
4. Hypoxia is a key regulator in liver cancer progression10.1016/j.jhep.2021.05.032 ↗
5. Hypoxia-driven immunosuppression by treg and type-2 conventional dendritic cells in hcc10.1002/hep.32419 ↗
6. Recent advances and future directions in sonodynamic therapy for cancer treatment10.34133/bmef.0080 ↗
7. An oxygen-generating nanoplatform remodels the immunosuppressive tumor microenvironment via synergistic lactate depletion and sonodynamic therapy10.1186/s12951-025-03524-6 ↗
8. Easl clinical practice guidelines on the management of hepatocellular carcinoma10.1016/j.jhep.2024.08.028 ↗
9. Synergistic sdt/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms10.1186/s12951-024-02995-3 ↗
10. The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional chinese medicine10.1186/s12943-025-02378-8 ↗
11. Redefining the role of hypoxia-inducible factors (hifs) in oxygen homeostasis10.1038/s42003-025-07896-1 ↗
12. Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy10.1038/s41420-025-02682-8 ↗
13. The transition from hif-1 to hif-2 during prolonged hypoxia results from reactivation of phds and hif1a mrna instability10.1186/s11658-022-00408-7 ↗
14. Hypoxia, oxidative stress, and the interplay of hifs and nrf2 signaling in cancer10.1038/s12276-024-01180-8 ↗
15. Differential but complementary roles of hif-1alpha and hif-2alpha in the regulation of bone homeostasis10.1038/s42003-024-06581-z ↗
16. Siah2 regulates stability of prolyl-hydroxylases, controls hif1alpha abundance, and modulates physiological responses to hypoxia10.1016/j.cell.2004.06.001 ↗
17. Deletion of prolyl hydroxylase domain-containing enzyme 3 (phd3) in zebrafish facilitates hypoxia tolerance10.1016/j.jbc.2023.105420 ↗
18. Oxygen-dependent changes in binding partners and post-translational modifications regulate the abundance and activity of hif-1alpha/2alpha10.1126/scisignal.abf6685 ↗
19. Nanosonosensitizers with ultrasound-induced reactive oxygen species generation for cancer sonodynamic immunotherapy10.3389/fbioe.2021.761218 ↗
20. A hypoxia responsive nanoassembly for tumor specific oxygenation and enhanced sonodynamic therapy10.1016/j.biomaterials.2021.120822 ↗
21. Cold and hot tumors: from molecular mechanisms to targeted therapy10.1038/s41392-024-01979-x ↗
22. Transforming the "cold" tumors to "hot" tumors: strategies for immune activation10.1016/j.bcp.2025.117194 ↗
23. The tumor epr effect for cancer drug delivery: current status, limitations, and alternatives10.1016/j.addr.2022.114614 ↗
24. Stealth nanoparticles in oncology: facing the peg dilemma10.1016/j.jconrel.2022.09.002 ↗
25. Cancer-responsive multifunctional nanoplatform based on peptide self-assembly for highly efficient combined cancer therapy by alleviating hypoxia and improving the immunosuppressive microenvironment10.1021/acsami.2c20388 ↗
26. Hollow manganese dioxide nanoparticles for drug delivery and imaging10.1021/acsanm.4c02040 ↗
27. Inhibition of siah2 ubiquitin ligase by vitamin k3 (menadione) attenuates hypoxia and mapk signaling and blocks melanoma tumorigenesis10.1111/j.1755-148X.2009.00628.x ↗
28. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through hif/hey1/pink1 pathway10.1038/s41419-019-2155-3 ↗
29. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency10.1002/advs.202201734 ↗
30. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-pd-1/pd-l1 for residual tumors immunotherapy after rfa10.1186/s12951-023-02067-y ↗
31. Cox-2/pge2 axis regulates hif2alpha activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment10.1158/1078-0432.CCR-17-2725 ↗
32. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives10.1038/s41392-025-02249-0 ↗
33. The hif axes in cancer: angiogenesis, metabolism, and immune-modulation10.1016/j.tibs.2025.06.005 ↗
34. Hypoxia-induced vegf enhances tumor survivability via suppression of serum deprivation-induced apoptosis10.1038/sj.onc.1203814 ↗
35. Endothelial cell apoptosis in angiogenesis and vessel regression10.1007/s00018-017-2577-y ↗
36. The role of vegf in cancer-induced angiogenesis and research progress of drugs targeting vegf10.1016/j.ejphar.2023.175586 ↗
37. The bcl-2 protein family: opposing activities that mediate cell death10.1038/nrm2308 ↗
38. Nanomedicine in cancer therapeutics: current perspectives from bench to bedside10.1186/s12943-025-02368-w ↗
39. Stromal hif2 regulates immune suppression in the pancreatic cancer microenvironment10.1053/j.gastro.2022.02.024 ↗
40. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
41. Targeting hif-2alpha in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade10.1007/s00018-025-05642-8 ↗
42. Tumor-targeting nanomaterials based on metal-organic frameworks mediate tumor immunotherapy by promoting cuproptosis and pyroptosis in hepatocellular carcinoma cells
43. Tumor vascular occlusion by calcium-based thermosensitizer provokes continuous cavitation effect and thermal energy transition efficiency of radiofrequency ablation therapy10.1016/j.biomaterials.2024.122944 ↗
44. Bimetallic ca/zn nanoagonist remould the immunosuppressive hepatocellular carcinoma microenvironment following incomplete microwave ablation via pyroptosis and the sting signaling pathway10.1002/advs.202500670 ↗
45. Aasld practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma10.1097/HEP.0000000000000466 ↗
46. Systemic therapy for advanced hepatocellular carcinoma: Asco guideline update10.1200/JCO.23.02745 ↗
47. Angiogenic signaling pathways and anti-angiogenic therapy for cancer10.1038/s41392-023-01460-1 ↗
48. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives10.1186/s13045-024-01647-1 ↗
49. Lenvatinib recruits cytotoxic gzmk+cd8 t cells in hepatocellular carcinoma10.1097/HC9.0000000000000209 ↗
50. Lenvatinib enhances antitumor immunity by promoting the infiltration of tcf1(+) cd8(+) t cells in hcc via blocking vegfr210.1111/cas.15719 ↗
51. Hypoxia-responsive ppargc1a/bambi/acsl5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma10.1038/s41388-023-02665-y ↗
52. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation10.1038/s41401-022-01021-2 ↗
53. Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy10.1111/liv.15953 ↗
54. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors10.1007/s12032-021-01503-z ↗